Moogene Medi Co., Ltd. (XKON: 322970)

Market Cap	23.79B
Revenue	n/a
Net Income	n/a
Shares Out	10.02M
EPS	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	968
Open	2,360.00
Previous Close	2,300.00
Day's Range	2,300.00 - 2,360.00
52-Week Range	1,350.00 - 3,385.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Moogene Medi

Moogene Medi Co., Ltd. develops gene therapies based on its proprietary gene-editing platform technology. The company’s product portfolio comprises MG-001, which is in Phase I clinical trials to treat colon cancer; MG-002 that is in preclinical stage for use in the treatment of pancreatic cancer; and MG-003, which is in preclinical stage for use in the treatment of diabetes mellitus. Its research stage products include MG-004 for treating hair loss and MG-005 for use in the treatment of Crohn's disease. The company was founded in 2016 and is ba...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Country: South Korea
• Stock Exchange: Korea New Exchange
• Ticker Symbol: 322970